Abstract
Patients with cancer and infectious diseases often have changes in the composition and concentration of their different blood components. These changes include variations in the composition and concentration of plasma lipoprotein lipids, in transfer rates of endogenous lipid between different lipoprotein classes, and in concentrations of phagocytic cells (i.e., monocytes and macrophages). It appears that the interaction of many lipid-based drug formulations with plasma lipoproteins and blood phagocytic cells may be responsible for the unpredictable pharmacokinetics and pharmacodynamics of those compounds when administered to patients with diseases. This review examines the potential mechanisms that may explain the biological behavior of lipid-based drug formulations used in the treatment of infectious diseases and cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
